STOCK TITAN

Monthly information on share capital and company voting rights

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Cellectis, a company listed on Euronext Growth, has a total of 55,583,768 shares in its capital and 61,519,396 voting rights as of October 31, 2023.
Positive
  • None.
Negative
  • None.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Nov. 03, 2023 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares
in the capital
Total number of voting rights
10/31/202355,583,76861,519,396

For further information on Cellectis, please contact:     

Media contact:       

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@cellectis.com 

Investor Relations contacts:       

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com       

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577  

 

Attachment


FAQ

What is the ISIN code for Cellectis?

The ISIN code for Cellectis is FR0010425595.

Who is the media contact for Cellectis?

The media contact for Cellectis is Patricia Sosa Navarro, Chief of Staff to the CEO. She can be reached at +33 (0)7 76 77 46 93 or media@cellectis.com.

Who are the investor relations contacts for Cellectis?

The investor relations contacts for Cellectis are Arthur Stril, Chief Business Officer, who can be reached at +1 (347) 809 5980 or investors@cellectis.com, and Ashley R. Robinson from LifeSci Advisors, who can be reached at +1 617 430 7577.

Cellectis S.A. American Depositary Shares

NASDAQ:CLLS

CLLS Rankings

CLLS Latest News

CLLS Stock Data

215.14M
33.22M
12.13%
18.83%
0.94%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Paris

About CLLS

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.